Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Selection trends of assistive technology devices by occupational therapists when supporting children with developmental disabilities in Japanese childcare settings.

Disability and rehabilitation. Assistive technology·2026

Same author

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Journal of gastroenterology and hepatology·2026

Same author

AAV9/hGLA gene therapy reduces podocyte GL-3 accumulation in a Fabry disease mouse model.

Molecular genetics and metabolism·2026

Same author

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Same author

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Same author

On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma.

Cancers·2026

Search research articles

Related Experiment Video

Updated: May 30, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus

Kazuto Tajiri¹, Yuka Hayashi¹, Aiko Murayama¹

¹Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

|January 25, 2025

Summary

Switching to tenofovir alafenamide fumarate (TAF) may decrease hepatitis B surface antigen (HBsAg) in some chronic hepatitis B patients, especially those with lower baseline HBsAg levels and mild fibrosis. TAF was well-tolerated in this study.

Keywords:

HBsAg decrease dyslipidemia hepatitis B virus nucleos(t)ide analogue switching tenofovir alafenamide fumarate

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Experiment Videos

Last Updated: May 30, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Hepatitis B virus (HBV) infection is a global health concern.
Nucleos(t)ide analogues (NAs) are standard treatment for chronic hepatitis B (CHB).
Achieving HBsAg seroclearance remains a challenge in CHB management.

Purpose of the Study:

To evaluate the effect of switching from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) on HBsAg levels in CHB patients.
To assess the safety and tolerability of TAF in this patient population.
To identify factors associated with HBsAg reduction after switching to TAF.

Main Methods:

Retrospective study of 77 CHB patients.
47 patients switched from ETV to TAF.
Median follow-up of 40 months post-switch; median 60 months HBsAg monitoring pre-switch.

Main Results:

No significant overall change in HBsAg levels post-switch.
Significant HBsAg decrease observed in patients with baseline HBsAg < 100 IU/mL.
HBsAg loss occurred in three patients switching to TAF.
TAF was well-tolerated with no adverse effects.
Higher Fib-4 index (liver fibrosis marker) at switch was associated with decreased HBsAg.

Conclusions:

Switching from ETV to TAF can be an effective strategy for managing CHB.
Hepatic inflammation, indicated by Fib-4 index, may play a role in HBsAg reduction.
Patients with mild to moderate fibrosis may benefit more from TAF regarding HBsAg reduction.